MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2024 International Congress

    Opicapone as First-Line Strategy for the Treatment of Wearing-off in Patients with Parkinson’s Disease

    J. Ferreira, J. Lee, H. Ma, B. Jeon, W. Poewe, A. Antonini, F. Stocchi, D. Rodrigues, M. Fonesca, J. Rocha, G. Castilla-Fernández, J. Holenz, O. Rascol (Lisbon, Portugal)

    Objective: The Korean and European ADOPTION studies aimed to explore the efficacy of opicapone (OPC) 50 mg versus an additional 100 mg levodopa dose to…
  • 2024 International Congress

    AccessPD Registry Update: Accelerating Parkinson’s Disease Research Through Integrated Digital Solutions

    Y-H. Chang, M. Periñan, A. Noyce (London, United Kingdom)

    Objective: To update on AccessPD's progress, emphasising the growth in patient recruitment, data integration, and the preliminary analysis aimed at advancing Parkinson's disease (PD) research.…
  • 2024 International Congress

    A Comparative Bioavailability Study between a Marketed Capsule-based Levodopa Dry Powder Inhaler and a New Pre-filled Levodopa Dry Powder Inhaler

    T. van Laar, F. Grasmeijer, M. Hoppentocht (Groningen, Netherlands)

    Objective: The primary objective was to determine the comparative bioavailability between a marketed and a new levodopa dry powder inhaler (DPI) with an enhanced usability…
  • 2024 International Congress

    Estimating the Proportion of Parkinson’s Disease Clinical Trial Subjects Who Showed No Measurable MDS-UPDRS Motor Score Progression Over 1 Year

    M. Pang, J. Edgerton, L. Zhu, S. Belachew, D. Taylor, C. Kanzler, M. Yang, F. Nahab, C. Shen (Cambridge, USA)

    Objective: To determine what percentage of subjects with early Parkinson’s disease demonstrated no measurable worsening of MDS-UPDRS motor scores over 52 weeks in a Phase…
  • 2024 International Congress

    Non-interventional phase 0 study for the collection of biospecimens from patients with Parkinson’s Disease (PD) to support the development of a diagnostic classifier for LRRK2-driven PD

    L. Desnoyers, S. Dheerendra, C. Wong, T. Dang, S. Esmaeeli, M. van Derbrug, M. Nalls, A. Ellenbogen, S. Jackson (South San Francisco, USA)

    Objective: Measure LRRK2 pathway activity in Parkinson’s Disease patients stratified using a genetic predictive classifier model. Background: Extensive research has shown that overactivation of the…
  • 2024 International Congress

    Overview of Phase 3 Trials of Continuous Subcutaneous Apomorphine Infusion for PD Patients with Motor Fluctuations

    R. Pahwa, T. van Laar, K. Dashtipour, G. Ceresoli-Borroni (Kansas City, USA)

    Objective: Review available efficacy data from Phase 3 studies assessing continuous subcutaneous apomorphine infusion (CSAI) for patients with PD experiencing motor fluctuations. Background: Despite decades…
  • 2024 International Congress

    Neuroprotective Action of Betulin in Parkinson’s disease: Alleviating Mitochondrial Dysfunction and Oxidative Stress-Induced Apoptosis in rat model

    A. Kumar (Allahabad, India)

    Objective: The objective of this study was to evaluate the neuroprotective efficacy of Betulin in MPTP-induced mice models of Parkinson's disease (PD), focusing on its…
  • 2024 International Congress

    Autoradiography characterization of novel alpha-synuclein radioligands [3H]Tg1-90B, [3H]M503-1619 and [3H]HY-2-15 in human post mortem brain

    D. Saturnino Guarino, G. Tian, K. Ho Young, H. Cj, V. Lee, K. Luk, R. Mach (Philadelphia, USA)

    Objective: To characterize the in vitro binding properties of 3 radioligands for imaging α-syn aggregates in post mortem brain samples of synucleinopathies: [3H]TG-190B (Site 2),…
  • 2024 International Congress

    Attitudes and Beliefs Towards Medication Burden and Deprescribing in Parkinson Disease

    TP. Pham Nguyen, D. Thibault, A. Hamedani, A. Willis (Philadelphia, USA)

    Objective: To examine the attitudes and beliefs about medication burden and deprescribing among persons living with Parkinson disease (PD) Background: Deprescribing of potentially inappropriate medications…
  • 2024 International Congress

    Clinical benefit of Opicapone in patients with different Parkinson disease phenopytes. The OPTIMO study

    MR. Luquin, C. Martin, I. Tegel, I. Pijuan, C. Moreno (Pamplona, Spain)

    Objective: To assess the clinical benefit induced by opicapone (OPC) as an add-on therapy to levodopa in fluctuating Parkinson’s disease (PD) patients with special focus…
  • « Previous Page
  • 1
  • …
  • 172
  • 173
  • 174
  • 175
  • 176
  • …
  • 181
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • An atypical and interesting feature of Parkinson´s disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Movement disorders in chronic obstructive pulmonary disease (COPD); the effect of pulmonary disease to brain
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley